ASCO: Avastin Improves Survival in Advanced Cervical Cancer

Results from the phase III GOG 240 trial, presented at ASCO, showed the addition of bevacizumab (Avastin) to standard chemotherapy improved overall survival by nearly 4 months in women with advanced or relapsed cervical cancer.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news